5-Amino-1MQ Overview
Category:
Small-molecule NNMT inhibitor
How it works:
Inhibits nicotinamide N-methyltransferase (NNMT), lowering production of 1-methyl-nicotinamide (1-MNA), conserving nicotinamide for NAD⁺ salvage, which increases cellular NAD⁺ and shifts metabolism away from fat storage.
Alternative names:
5-amino-1-methylquinolinium, 5A1MQ, 5-Amino-1MQ
Primary research focus:
- Metabolic disease (obesity, insulin resistance)
- Adipocyte biology
- NAD⁺ metabolism
- Aging-related muscle function in preclinical models
Potential risks:
Mostly preclinical evidence; limited/no controlled human data to define safety, dosing, or long-term risks.
What is 5-Amino-1MQ?
5-Amino-1MQ (often written 5A1MQ or 5-amino-1-methylquinolinium) is a research small molecule developed to selectively inhibit NNMT, an enzyme that methylates nicotinamide (NAM) to 1-MNA. NNMT is upregulated in obesity, fatty liver, and some metabolic disorders; inhibiting it is hypothesized to shift cellular metabolism by increasing available NAM for NAD⁺ salvage and changing methyl donor (SAM) use. Most evidence comes from cell culture and rodent studies.
How it works in the body
- NNMT blockade: By blocking NNMT, 5-Amino-1MQ reduces conversion of nicotinamide → 1-MNA. That leads to higher intracellular nicotinamide available for the NAD⁺ salvage pathway.
- NAD⁺ increase: More substrate for NAD⁺ salvage tends to raise NAD⁺ pools in cells — implicating downstream effects on sirtuins, mitochondrial function, oxidative metabolism, and cellular energy balance.
- Metabolic reprogramming in adipocytes: In adipocyte models, NNMT inhibition suppresses lipogenesis and reduces adipocyte differentiation/size, producing less fat accumulation.
- Systemic metabolic effects: In diet-induced obese (DIO) mice, NNMT inhibition with 5-Amino-1MQ produced progressive weight and fat loss, improved glucose handling, reduced plasma insulin and improved liver pathology in several studies. These are mechanistically consistent with improved cellular NAD⁺ and altered methylation/energetics.
5-Amino-1MQ Benefits
1. Body-weight and fat mass reduction (preclinical):
Multiple rodent studies report that systemic treatment with 5-Amino-1MQ produced meaningful reductions in body weight, white adipose mass, and adipocyte size in high-fat diet models. Effects were observed with short-term dosing and in combination with dietary changes produced durable fat loss in mice.
2. Improved glucose tolerance and insulin sensitivity:
In DIO mice, 5-Amino-1MQ dose-dependently lowered fed-state insulin and improved oral glucose tolerance tests, suggesting improved insulin sensitivity. This aligns with reduced adiposity and improved hepatic/metabolic function in preclinical work.
3. Increased cellular NAD⁺ and mitochondrial resilience:
By preserving nicotinamide for NAD⁺ salvage, NNMT inhibitors increase NAD⁺ — a cofactor central to mitochondrial health and sirtuin activity. Studies link 5-Amino-1MQ treatment with biochemical markers consistent with higher NAD⁺ and improved metabolic signaling.
4. Suppression of lipogenesis and improved adipocyte phenotype:
Cell culture studies show NNMT inhibition reduces expression of lipogenic genes and lipid accumulation in adipocytes, offering a cell-level explanation for reduced fat mass in animals.
5. Muscle strength and regenerative potential (early aging models):
Emerging preclinical work reports improved muscle strength, endurance, and regenerative capacity in aged mice treated with NNMT inhibitors — suggesting potential for sarcopenia research, though this is very early.
6. Liver and cardiometabolic improvements:
Some studies combining NNMT inhibition with lifestyle change report improvements in fatty liver and metabolic markers beyond diet alone in mice.
Clinical studies
- Human trials: As of the sources above, there are no well-powered published randomized controlled trials in humans for 5-Amino-1MQ. Research remains preclinical (cellular and multiple mouse models) and investigator-initiated animal studies have shown promising efficacy signals.
- Preclinical evidence base: The foundational Biochemical Pharmacology / PMC paper (Neelakantan et al.) demonstrated that selective, membrane-permeable methylquinolinium NNMT inhibitors including 5-Amino-1MQ reverse high-fat diet induced obesity in mice and increase intracellular NAD⁺ while lowering 1-MNA. Multiple subsequent reviews and reports (2021–2024) summarize these findings and expand on potential translational uses.
Safety, side effects, and considerations
Safety summary: Clinical safety data for 5-Amino-1MQ in humans are lacking. Animal studies have not reported the kind of acute toxicities that would preclude research use, but animal tolerability does not guarantee human safety. Long-term effects, off-target actions, and interactions with methylation/metabolite pools (SAM cycle) require careful study.
Known/potential concerns:
- No established human dosing or formulation. Research doses in mice (mg/kg range, multiple daily doses in short studies) do not translate directly to human dosing.
- Methylation balance: NNMT sits at an intersection of nicotinamide and methyl donor (SAM) metabolism. Long-term inhibition could theoretically alter methylation reactions; consequences are unknown and should be studied.
- Off-target effects and selectivity: Published reports highlight good selectivity of methylquinolinium analogues for NNMT vs. other SAM-dependent methyltransferases, but complete off-target profiling in humans is missing.
- Cancer/angiogenesis concerns: Some metabolic modulators raise theoretical concerns about effects on proliferative tissues. There is no clear evidence that 5-Amino-1MQ promotes tumors, but absence of evidence is not evidence of absence; rigorous long-term safety testing is needed.
Practical guidance (research context only):
- 5-Amino-1MQ is an investigational research compound; it is not FDA-approved for clinical use. Use should be restricted to controlled research settings under regulatory oversight.
- If you’re reading vendor pages or clinics offering human use, treat claims with caution — they are often extrapolations from rodent data, not human evidence.
Bottom line
5-Amino-1MQ is a selective NNMT inhibitor with compelling preclinical evidence for improving metabolic health in rodents: reduced fat mass, better glucose handling, increased intracellular NAD⁺, and promising signals for muscle health. However, human data are minimal or absent, and safety, dosing, and long-term effects are not established. It’s an exciting translational candidate — but at present it belongs to the “promising in animals / investigational” category, not a clinically validated therapy.
